HLS Therapeutics (TSE:HLS) Sets New 52-Week High - Here's What Happened

Key Points

• HLS Therapeutics' stock reached a new 52-week high of C$5.65, outpacing the previous close, indicating positive market momentum.
• Raymond James Financial upgraded HLS Therapeutics from a "hold" to a "moderate buy" rating, with an increased price target of C$6.00.
• The company's market capitalization is C$179.57 million, with notable financial ratios including a debt-to-equity ratio of 86.50 and a PE ratio of -11.92.

HLS Therapeutics Inc. (TSE:HLS - Get Free Report)'s share price reached a new 52-week high on Wednesday . The stock traded as high as C$5.65 and last traded at C$5.60, with a volume of 4711 shares trading hands. The stock had previously closed at C$5.65.

Analyst Ratings Changes

Separately, Raymond James Financial raised shares of HLS Therapeutics from a "hold" rating to a "moderate buy" rating and lifted their price target for the company from C$5.00 to C$6.00 in a research note on Thursday, August 21st. One research analyst has rated the stock with a Hold rating, According to MarketBeat.com, the company has a consensus rating of "Hold" and an average target price of C$5.00.

HLS Therapeutics Trading Up 0.4%

The company has a quick ratio of 1.01, a current ratio of 1.56 and a debt-to-equity ratio of 86.50. The stock's 50 day moving average price is C$5.13 and its 200-day moving average price is C$4.74. The stock has a market capitalization of C$176.12 million, a P/E ratio of -11.69 and a beta of 0.65.

About HLS Therapeutics

HLS Therapeutics Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company is focused on treatment products for the central nervous system (CNS), and cardiovascular specialties. The company products include Clozaril, Absorica, Vascepa, CSAN Pronto, Trinomia and Perseris.